Literature DB >> 19382747

Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells.

Jonathan M Shaffer1, Sabine Hellwig, Thomas E Smithgall.   

Abstract

The c-fes proto-oncogene encodes a unique nonreceptor protein-tyrosine kinase (c-Fes) that contributes to the differentiation of myeloid hematopoietic, vascular endothelial, and some neuronal cell types. Although originally identified as the normal cellular homologue of the oncoproteins encoded by avian and feline transforming retroviruses, c-Fes has recently been implicated as a tumor suppressor in breast and colonic epithelial cells. Structurally, c-Fes consists of a unique N-terminal region harboring an FCH domain, two coiled-coil motifs, a central SH2 domain, and a C-terminal kinase domain. In living cells, c-Fes kinase activity is tightly regulated by a mechanism that remains unclear. Previous studies have established that c-Fes forms high molecular weight oligomers in vitro, suggesting that the dual coiled-coil motifs may regulate the interconversion of inactive monomeric and active oligomeric states. Here we show for the first time that c-Fes forms oligomers in live cells independently of its activation status using a YFP bimolecular fluorescence complementation assay. We also demonstrate that both N-terminal coiled-coil regions are essential for c-Fes oligomerization in transfected COS-7 cells as well as HCT 116 colorectal cancer and K-562 myeloid leukemia cell lines. Together, these data provide the first evidence that c-Fes, unlike c-Src, c-Abl, and other nonreceptor tyrosine kinases, is constitutively oligomeric in both its repressed and active states. This finding suggests that conformational changes, rather than oligomerization, may govern its kinase activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382747      PMCID: PMC3222594          DOI: 10.1021/bi900238f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  43 in total

1.  Regulation of c-Fes tyrosine kinase and biological activities by N-terminal coiled-coil oligomerization domains.

Authors:  H Cheng; J A Rogers; N A Dunham; T E Smithgall
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

2.  SH2-kinase linker mutations release Hck tyrosine kinase and transforming activities in Rat-2 fibroblasts.

Authors:  S D Briggs; T E Smithgall
Journal:  J Biol Chem       Date:  1999-09-10       Impact factor: 5.157

3.  The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner, substrate and activator of the c-Fes protein tyrosine kinase.

Authors:  Frank J Delfino; Jonathan M Shaffer; Thomas E Smithgall
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

4.  Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.

Authors:  Jonathan M Shaffer; Thomas E Smithgall
Journal:  Genes Chromosomes Cancer       Date:  2009-03       Impact factor: 5.006

Review 5.  BAR, F-BAR (EFC) and ENTH/ANTH domains in the regulation of membrane-cytosol interfaces and membrane curvature.

Authors:  Toshiki Itoh; Pietro De Camilli
Journal:  Biochim Biophys Acta       Date:  2006-07-28

6.  An identity crisis for fps/fes: oncogene or tumor suppressor?

Authors:  Waheed Sangrar; Ralph A Zirgnibl; Yan Gao; William J Muller; Zongchao Jia; Peter A Greer
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

7.  Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.

Authors:  Bhushan Nagar; Oliver Hantschel; Markus Seeliger; Jason M Davies; William I Weis; Giulio Superti-Furga; John Kuriyan
Journal:  Mol Cell       Date:  2006-03-17       Impact factor: 17.970

Review 8.  SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.

Authors:  Faye M Johnson; Gary E Gallick
Journal:  Anticancer Agents Med Chem       Date:  2007-11       Impact factor: 2.505

9.  Contributions of F-BAR and SH2 domains of Fes protein tyrosine kinase for coupling to the FcepsilonRI pathway in mast cells.

Authors:  Victor A McPherson; Stephanie Everingham; Robert Karisch; Julie A Smith; Christian M Udell; Jimin Zheng; Zongchao Jia; Andrew W B Craig
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

10.  Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.

Authors:  Panagis Filippakopoulos; Michael Kofler; Oliver Hantschel; Gerald D Gish; Florian Grebien; Eidarus Salah; Philipp Neudecker; Lewis E Kay; Benjamin E Turk; Giulio Superti-Furga; Tony Pawson; Stefan Knapp
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

View more
  1 in total

1.  Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.

Authors:  Sabine Hellwig; Chandra V Miduturu; Shigeru Kanda; Jianming Zhang; Panagis Filippakopoulos; Eidarus Salah; Xianming Deng; Hwan Geun Choi; Wenjun Zhou; Wooyoung Hur; Stefan Knapp; Nathanael S Gray; Thomas E Smithgall
Journal:  Chem Biol       Date:  2012-04-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.